Form 8-K - Current report:
SEC Accession No. 0001193125-24-186279
Filing Date
2024-07-26
Accepted
2024-07-26 16:36:00
Documents
17
Period of Report
2024-07-26
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d868344d8k.htm   iXBRL 8-K 30603
2 EX-1.1 d868344dex11.htm EX-1.1 203874
3 EX-5.1 d868344dex51.htm EX-5.1 11885
7 GRAPHIC g868344g0725074206089.jpg GRAPHIC 1649
8 GRAPHIC g868344g0725074928582.jpg GRAPHIC 6404
  Complete submission text file 0001193125-24-186279.txt   440395

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA alrn-20240726.xsd EX-101.SCH 2856
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE alrn-20240726_lab.xml EX-101.LAB 18757
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE alrn-20240726_pre.xml EX-101.PRE 11714
20 EXTRACTED XBRL INSTANCE DOCUMENT d868344d8k_htm.xml XML 3808
Mailing Address 12407 N. MOPAC EXPY. SUITE 250 #390 AUSTIN TX 78758
Business Address 12407 N. MOPAC EXPY. SUITE 250 #390 AUSTIN TX 78758 7378021989
Aileron Therapeutics, Inc. (Filer) CIK: 0001420565 (see all company filings)

EIN.: 134196017 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38130 | Film No.: 241147573
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)